Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Atrophic Gastritis Prevalence Determined by Serological Evidence

By LabMedica International staff writers
Posted on 19 Feb 2019
Gastric cancer, among the most common cancers, is a leading cause of cancer deaths worldwide. Gastric cancer incidence rates are highest in East Asia, followed by Central/East Europe and South America, with low rates in North America and Africa.

Helicobacter pylori is an established cause of distal gastric cancer (almost 90%). Infection with H. pylori strains expressing cytotoxin-associated gene A (CagA) antigen is associated with greater risk for gastric cancer. Gastric cancer develops in a progressive manner known as the Correa cascade.

Scientists at the Tel Aviv University Sackler Faculty of Medicine (Tel Aviv, Israel) and their colleagues used archived anonymized sera obtained in the framework of a cross-sectional study conducted in 2007 to 2008 among 692 Jewish and 952 Arab residents of Jerusalem, aged 25 to 78 years at the examination. The team examined the prevalence and correlates of serological evidence of atrophic gastritis, a premalignant gastric condition, using serum pepsinogens (PGs) in the two populations with differing trends in gastric cancer incidence.

The investigators quantified the concentrations of serum PGI and PGII were by enzyme-linked immunosorbent assays (ELISA) and PGI:PGII ratios were calculated. Atrophic gastritis was defined as a serum PGI level of <30 µg/L or a PGI:PGII ratio <3.0. Sera were also tested for the presence of specific H. pylori IgG antibodies using an ELISA Enzygnost Anti-H. pylori II/IgG kit. The sensitivity and specificity of the kit is 94% to 98%.

The scientists found that by using cut-offs of PGI <30µg/L or PGI:PGII <3.0, the prevalence of atrophic gastritis was higher among Arab than Jewish participants: 8.8% versus 5.9%, increasing with age in both groups. Among Jewish participants, infection with H. pylori CagA phenotype was positively related to atrophic gastritis: adjusted OR (aOR) = 2.16, but not to non-CagA infections aOR = 1.17 . The opposite was found among Arabs: aOR = 0.09 for CagA positive and aOR 0.15 for Cag A negative phenotypes. Women had higher atrophic gastritis prevalence than men. Obesity and smoking were not significantly related to atrophic gastritis; physical activity tended to be inversely associated in Arabs.

The authors concluded that ethnic differences were observed in the prevalence of atrophic gastritis and in its association with H. pylori seropositivity. The lowest PGI:PGII ratio was observed in persons infected with CagA strains, although this measure may discriminate less well in Arabs. The study was published on January 29, 2019, in the journal BMJ OPEN.

Related Links:
Tel Aviv University Sackler Faculty of Medicine


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV Test
Anti-HIV (1/2) Rapid Test Kit
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.